“Rituximab is licensed for inducing remission in adults with a type of vasculitis (inflammation of the blood
However, it is worth noting that the more robust analysis appears to be a consequence of the manufacturer accepting 14 of the changes to their original submission that were proposed by the Evidence Review Group and endorsed by the Committee. The ERG was ScHARR-TAG, and as reported previously, their work was of particular note in this appraisal due to the spectacularly different model structure and data sources they suggest should be used. The ScHARR-TAG team were Nick Latimer, Ruth Wong, Paul Tappenden and Chris Carroll. Looks like they were right.
Photo credit: epSos.de via Flickr Creative Commons